Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: pbi
Veröffentlicht am: 09.02.2018 07:57
Rubrik: Logistik & Verkehr

(Presseportal openBroadcast) - Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.
The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fuelling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.

A sample of this report is available upon request @

Uveitis treatment market segmented based on drug class, disease type, by cause and distribution channel

Based on drug class, uveitis treatment market is segmented into
• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Based on disease type, uveitis treatment market is segmented into
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Based on cause, uveitis treatment market is segmented into
• Infectious Uveitis
• Non-Infectious Uveitis

Based on distribution channel, uveitis treatment market is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others

To view TOC of this report is available upon request @

Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing luveniq, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at significant rate during forecast period.

Need more information about this report @

Geographically uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis are contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations are very high that have direct implication on cost of the drugs.

Some of the players in uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few.

Get access to full summary @



Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.